<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01475214</url>
  </required_header>
  <id_info>
    <org_study_id>2705</org_study_id>
    <secondary_id>R01AR060261</secondary_id>
    <nct_id>NCT01475214</nct_id>
  </id_info>
  <brief_title>Musculoskeletal Effects of Bicarbonate</brief_title>
  <official_title>Musculoskeletal Benefits of Bicarbonate in Older Adults - A Dose-Finding Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With aging, men and women develop a mild and progressive metabolic acidosis. This occurs as a
      result of declining renal function and ingestion of acid-producing diets. There is extensive
      evidence that severe metabolic acidosis causes bone and muscle loss, but the impact of the
      chronic, mild acidosis on bone and muscle in older individuals has not been established. In a
      recent study, administration of a single dose of bicarbonate daily for 3 months significantly
      reduced urinary excretion of N-telopeptide (NTX), a marker of bone resorption and urinary
      nitrogen, a marker of muscle wasting and improved muscle performance in the women but not the
      men. These and other data support a potential role for bicarbonate as a means of reducing the
      musculoskeletal declines that lead to extensive morbidity and mortality in the elderly.
      Before proceeding to a long-term bicarbonate intervention study, however, it is important to
      identify the dose of bicarbonate most likely to be optimal and to characterize the subjects
      who benefit most from it. This double blind, placebo controlled, dose-finding study will
      evaluate the effects of placebo and two doses of bicarbonate on urinary NTX and nitrogen
      excretion and on lower extremity performance over a 3 month period in 138 men and 138 women,
      age 60 and older. Changes in urinary excretion of NTX and nitrogen and in selected measures
      of lower extremity performance will be compared across the three groups. The safety and
      tolerability of the interventions will also be evaluated. This investigation should provide
      needed information on the appropriate dosing regimen for men and women and on the study
      population that should be enrolled in a future bicarbonate intervention trial to assess the
      long-term effects of this simple, low cost intervention on important clinical outcomes
      including rates of loss in bone and muscle mass, falls, and fractures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This dose-finding study will evaluate the effects of placebo and two doses of bicarbonate on
      urinary NTX and nitrogen excretion and on lower extremity performance over a three month
      period. The lower dose is similar to the dose shown in our recent trial to be effective. This
      study is a double blind, randomized, placebo-controlled, parallel-group trial in which 138
      healthy men and 138 women, age 60 and older, will take potassium bicarbonate in doses of 1.0
      or 1.5 mmol/kg of body weight or placebo daily for three months. Changes in urinary excretion
      of NTX and nitrogen and in measures of lower extremity performance will be compared across
      the three groups. The safety and tolerability of the interventions will also be evaluated.
      This investigation should provide needed information on the appropriate dosing regimen and on
      the study population that should be enrolled in a future bicarbonate intervention trial to
      assess the long-term effects of this simple, low cost intervention on important clinical
      outcomes including rates of loss in bone and muscle mass, falls, and fractures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</measure>
    <time_frame>84 days</time_frame>
    <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</measure>
    <time_frame>84 days</time_frame>
    <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Muscle Loss</condition>
  <condition>Fractures</condition>
  <condition>Osteoporosis, Age Related</condition>
  <condition>Fall Injury</condition>
  <arm_group>
    <arm_group_label>potassium bicarbonate low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>potassium bicarbonate higher dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>microcrystalline cellulose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>potassium bicarbonate</intervention_name>
    <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
    <arm_group_label>potassium bicarbonate low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>potassium bicarbonate</intervention_name>
    <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
    <arm_group_label>potassium bicarbonate higher dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inactive placebo capsule</intervention_name>
    <description>microcrystalline cellulose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women

          -  age 60 and older

          -  community dwelling

          -  women 1 yr since last menses

        Exclusion Criteria:

        Medications:

          1. Oral glucocorticoids for &gt; 10 days in the last 3 months

               -  Cortef (hydrocortisone)

               -  Prednisone

          2. Parenteral glucocorticoids

             • Decadron (dexamethasone)

          3. Osteoporosis medications in the last 6 months

               -  Forteo (teriparatide)

               -  Calcimar, Miacalcin (calcitonin)

               -  Evista (raloxifene)

          4. Osteoporosis medications in the last 2 years

               -  Fosamax (alendronate)

               -  Didronel (etidronate)

               -  Aredia (pamidronate)

               -  Actonel (risedronate)

               -  Reclast (zoledronate)

          5. Tamoxifen in the last 6 months

          6. Calcium/Parathyroid

               -  Rocaltrol (calcitriol)

               -  Zemplar (paricalcitol)

               -  Drisdol, Ergocalciferol

          7. Diuretics currently

               -  hydrocholorothiazide (HCTZ)

               -  Diuril (chlorothiazide)

               -  Thalitone (chlorthalidone)

               -  Zaroxolyn (metolazone)

               -  Dyazide

               -  Maxide

               -  Moduretic

               -  Lasix (forosamine)

               -  Dyrenium (triamterene)

               -  Midamor

          8. Testosterone or estrogen in the last 6 months (vaginal estrogen okay)

          9. Angiotensin converting enzyme (ACE) inhibitors currently

               -  Benazepril (Lotensin)

               -  Captopril (Capoten)

               -  Enalapril (Vasotec)

               -  Fosinopril (Monopril)

               -  Lisinopril (Prinivil, Zestril)

               -  Moexipril (Univasc)

               -  Perindopril (Aceon)

               -  Quinapril (Accupril)

               -  Ramipril (Altace)

               -  Trandolapril (Mavik)

         10. Angiotensin II receptor blockers currently

               -  Candesartan (Atacand)

               -  Eprosartan (Teveten)

               -  Irbesartan (Avapro)

               -  Losartan (Cozaar)

               -  Olmesartan (Benicar)

               -  Telmisartan (Micardis)

               -  Valsartan (Diovan)

        Over-the-Counter Drugs currently

          1. Antacids - any antacid that contains calcium carbonate, aluminum hydroxide, magnesium
             hydroxide, or calcium acetate - selected examples include

               -  TUMS

               -  Mylanta

               -  Maalox

               -  Titralac

               -  Rolaids

               -  Sodium bicarbonate (baking soda)

               -  Note: magaldrate or Riopan® is allowed

          2. Potassium supplements

          3. Salt substitutes

        Conditions/Diseases

          1. renal disease including kidney stones in the past 5 years or glomerular filtration
             rate (GFR) &lt; 60 ml/min/1.73 m2

          2. hyperkalemia (serum potassium &gt;5.3 meq/L; normal range 3.5-5.3 meq/L)

          3. elevated serum bicarbonate (serum bicarbonate &gt; 29 mmol/L; normal range 22-29 mmol/L)

          4. cirrhosis

          5. gastroesophageal reflux disease (GERD) requiring treatment with alkali-containing
             antacids (TUMS, Mylanta, Maalox, Titralac, Rolaids, or sodium bicarbonate)

          6. hyperparathyroidism

          7. untreated thyroid disease

          8. significant immune disorder such as rheumatoid arthritis

          9. current unstable heart disease

         10. active malignancy or cancer therapy in the last year

         11. fasting spot urine calcium/creatinine &gt; 0.38 mmol/mmol after 1 wk off of calcium
             supplements

         12. congestive heart failure, arrhythmias (surgically treated arrhythmias acceptable), or
             myocardial infarction in last 12 months

         13. serum calcium outside the normal range of 8.3-10.2 mg/dl

         14. uncontrolled diabetes mellitus (fasting blood sugar &gt; 130)

         15. alcohol use exceeding 2 drinks/day

         16. peptic ulcers or esophageal stricture

         17. weight &lt;45 or &gt;113.5 kg (&lt;99 or &gt;249.7 lbs)

         18. other abnormalities in screening labs, at discretion of the study physician (the PI)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2011</study_first_posted>
  <results_first_submitted>June 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2015</results_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tufts University</investigator_affiliation>
    <investigator_full_name>Bess Dawson-Hughes</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>potassium bicarbonate</keyword>
  <keyword>urinary N-telopeptide</keyword>
  <keyword>urinary nitrogen</keyword>
  <keyword>net acid excretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="P2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="P3">
          <title>Inactive Capsule</title>
          <description>microcrystalline cellulose
placebo: microcrystalline cellulose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="B2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="B3">
          <title>Inactive Placebo Capsule</title>
          <description>microcrystalline cellulose
placebo: microcrystalline cellulose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="84"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="244"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="5.5"/>
                    <measurement group_id="B2" value="66.4" spread="5.1"/>
                    <measurement group_id="B3" value="66.8" spread="6.1"/>
                    <measurement group_id="B4" value="66.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian, Non-hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian, Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="13.7"/>
                    <measurement group_id="B2" value="74.2" spread="13.0"/>
                    <measurement group_id="B3" value="73.2" spread="14.0"/>
                    <measurement group_id="B4" value="74.1" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular Filtration Rate (GFR)</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.5" spread="13.2"/>
                    <measurement group_id="B2" value="77.5" spread="12.8"/>
                    <measurement group_id="B3" value="74.8" spread="12.9"/>
                    <measurement group_id="B4" value="76.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum potassium</title>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.31" spread="0.29"/>
                    <measurement group_id="B2" value="4.39" spread="0.36"/>
                    <measurement group_id="B3" value="4.30" spread="0.31"/>
                    <measurement group_id="B4" value="4.33" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum bicarbonate</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.1" spread="1.9"/>
                    <measurement group_id="B2" value="25.8" spread="2.4"/>
                    <measurement group_id="B3" value="26.1" spread="2.4"/>
                    <measurement group_id="B4" value="26.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine calcium/creatinine</title>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99" spread="43"/>
                    <measurement group_id="B2" value="99" spread="48"/>
                    <measurement group_id="B3" value="114" spread="69"/>
                    <measurement group_id="B4" value="104" spread="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</title>
        <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
        <time_frame>84 days</time_frame>
        <population>Healthy men and women age 60 years and older</population>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate Low Dose</title>
            <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Potassium Bicarbonate Higher Dose</title>
            <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Inactive Placebo Capsule</title>
            <description>microcrystalline cellulose
placebo: microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide</title>
          <description>Describe and compare changes in urinary N-telopeptide (NTX) across the placebo and Potassium Bicarbonate (KHCO3) doses.</description>
          <population>Healthy men and women age 60 years and older</population>
          <units>nmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 24-hr urinary NTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" spread="17"/>
                    <measurement group_id="O2" value="230" spread="20"/>
                    <measurement group_id="O3" value="241" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change in NTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53" spread="11"/>
                    <measurement group_id="O2" value="-43" spread="11"/>
                    <measurement group_id="O3" value="-14" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</title>
        <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
        <time_frame>84 days</time_frame>
        <population>healthy men and women age 60 years and older</population>
        <group_list>
          <group group_id="O1">
            <title>Potassium Bicarbonate Low Dose</title>
            <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O2">
            <title>Potassium Bicarbonate Higher Dose</title>
            <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
          </group>
          <group group_id="O3">
            <title>Inactive Capsule</title>
            <description>microcrystalline cellulose
placebo: microcrystalline cellulose</description>
          </group>
        </group_list>
        <measure>
          <title>Co-primary Aim - to Identify the Dose of KHCO3 Needed for Maximal Suppression of 24-hr Urinary Nitrogen</title>
          <description>Describe and compare changes in 24-hour urinary nitrogen in the low and high dose and KHCO3 group and in placebo.</description>
          <population>healthy men and women age 60 years and older</population>
          <units>mmol/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline 24-hr urine nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769" spread="32"/>
                    <measurement group_id="O2" value="834" spread="39"/>
                    <measurement group_id="O3" value="864" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change in 24-hr urine nitrogen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.4" spread="18.6"/>
                    <measurement group_id="O2" value="-16.4" spread="19.1"/>
                    <measurement group_id="O3" value="-21.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Potassium Bicarbonate Low Dose</title>
          <description>potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="E2">
          <title>Potassium Bicarbonate Higher Dose</title>
          <description>potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
potassium bicarbonate: potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water</description>
        </group>
        <group group_id="E3">
          <title>Inactive Capsule</title>
          <description>microcrystalline cellulose
placebo: microcrystalline cellulose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <description>Bloating, dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusions/abrasions</sub_title>
                <description>Resulting from falls</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Fracture, right wrist, from fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>High serum potassium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI upset</sub_title>
                <description>GI upset, heartburn, gas, bloating, nausea</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Constipation/diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache, migraine</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Fever, fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Mouth irritation</sub_title>
                <description>Roof of mouth irritation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee/hip injury</sub_title>
                <description>Sprain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <description>Reports numbness in thumb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>High serum potassium</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Potassium level &gt; 5.3 meq/L</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="79"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>low GFR</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Reported if GFR &lt; 55; protocol change GFR &lt; 45</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bess Dawson-Hughes</name_or_title>
      <organization>Jean Mayer Human Nutrition Research Center on Aging at Tufts University</organization>
      <phone>617-556-3066</phone>
      <email>bess.dawson-hughes@tufts.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

